Ovid Therapeutics Inc.
$2.89
▲
1.85%
2026-04-21 08:42:01
www.ovidrx.com
NCM: OVID
Explore Ovid Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$381.12 M
Current Price
$2.89
52W High / Low
$3.1 / $0.27
Stock P/E
—
Book Value
$1
Dividend Yield
—
ROCE
-29.75%
ROE
-17.51%
Face Value
—
EPS
$-0.23
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
23
Beta
-0.03
Debt / Equity
10.27
Current Ratio
8.97
Quick Ratio
8.97
Forward P/E
-5.87
Price / Sales
57.27
Enterprise Value
$306.44 M
EV / EBITDA
-7.27
EV / Revenue
42.26
Rating
Strong Buy
Target Price
$5.01
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Anavex Life Sciences Corp. | $3.65 | — | $338.25 M | — | -54.15% | -33.63% | $13.99 / $2.61 | $1.37 |
| 2. | Tyra Biosciences, Inc. | $34.37 | — | $1.92 B | — | -50.19% | -39.83% | $40.65 / $7.8 | $4.83 |
| 3. | Ocular Therapeutix, Inc. | $9.52 | — | $2.09 B | — | -35.66% | -54.85% | $16.44 / $6.23 | $3.03 |
| 4. | Monte Rosa Therapeutics, Inc. | $19.81 | — | $1.58 B | — | -14.1% | -16.94% | $25.77 / $3.51 | $3.56 |
| 5. | NewAmsterdam Pharma Company N.V. | $33.82 | — | $3.89 B | — | -33.02% | -28.29% | $42 / $15.82 | $5.97 |
| 6. | Cogent Biosciences, Inc. | $37 | — | $6.05 B | — | -38.16% | -73.7% | $43.73 / $4.12 | $3.4 |
| 7. | Immatics N.V. | $11.25 | — | $1.51 B | — | -35.05% | -37.1% | $12.41 / $3.94 | $4.18 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.72 M | 0.13 M | 6.27 M | 0.13 M | 0.08 M | — |
| Operating Profit | -12.29 M | -12.52 M | -5.07 M | -12.55 M | -10.72 M | — |
| Net Profit | 9.66 M | -12.16 M | -4.68 M | -10.23 M | -9.25 M | — |
| EPS in Rs | 0.06 | -0.08 | -0.03 | -0.07 | -0.06 | -0.2 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 7.25 M | 0.57 M | 0.39 M | 1.5 M |
| Operating Profit | -42.44 M | -61.88 M | -59.28 M | -55.55 M |
| Net Profit | -17.41 M | -26.43 M | -52.34 M | -54.17 M |
| EPS in Rs | -0.12 | -0.18 | -0.35 | -0.36 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 150.93 M | 92.17 M | 144.03 M | 155.27 M |
| Total Liabilities | 20.27 M | 23.94 M | 56.23 M | 22.99 M |
| Equity | 130.66 M | 68.23 M | 87.8 M | 132.27 M |
| Current Assets | 74.37 M | 55.94 M | 109.6 M | 131.38 M |
| Current Liabilities | 8.29 M | 10.52 M | 11.47 M | 6.99 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -38.33 M | -55.96 M | -45.78 M | -55.23 M |
| Investing CF | -49.85 M | 54.59 M | -2.58 M | -87.88 M |
| Financing CF | 75.21 M | 0.62 M | 30.54 M | 0.18 M |
| Free CF | -38.33 M | -56.12 M | -45.92 M | -56.65 M |
| Capex | — | -0.16 M | -0.14 M | -1.42 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 44.39% | -73.91% | — | — |
| Earnings Growth % | 49.5% | 3.38% | — | — |
| Profit Margin % | -4670.14% | -13351.79% | -3604.66% | — |
| Operating Margin % | -10933.75% | -15122.7% | -3696.4% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -10825.44% | -14977.81% | -3604.47% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.